XLO – xilio therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Xilio Therapeutics, Inc. (NASDAQ: XLO) had its price target lowered by analysts at Raymond James from $6.00 to $4.00. They now have an "outperform" rating on the stock.
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results [Yahoo! Finance]
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Form SC 13G/A Xilio Therapeutics, Inc. Filed by: Bain Capital Life Sciences Fund II, L.P.
Form SC 13G/A Xilio Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Form SC 13G/A Xilio Therapeutics, Inc. Filed by: Rock Springs Capital Management LP
Form SC 13G/A Xilio Therapeutics, Inc. Filed by: FMR LLC
Form 10-Q Xilio Therapeutics, Inc. For: Sep 30
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.